Every 10-Q that Seres Therapeutics Inc (MCRB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MCRB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MCRB filings page.
Seres Therapeutics reported Q2 2026 results with grant revenue of $736 thousand and net income of $4,581 thousand, compared with a loss a year earlier. Profitability was driven by a $25,000 thousand gain from amending its VOWST sale agreement with Nestlé, which replaces large contingent sales milestones with a fixed Milestone Termination Payment.
Core operations remain loss-making, with a Q2 loss from operations of $21,273 thousand and $42,180 thousand for the first half. Cash and cash equivalents were $15,594 thousand at June 30, 2026, and operating activities used $38,754 thousand of cash year to date. Even after including the $25,000 thousand Nestlé payment (half received in July, half expected in October 2026), management disclosed conditions and events that raise substantial doubt about the company’s ability to continue as a going concern and highlighted the need for additional financing or partnerships.
The company continued restructuring, including a workforce reduction of about 30% and lease amendments that reduced its Cambridge footprint but triggered a $5,807 thousand impairment of long-lived assets. Development is focused on live biotherapeutic candidates SER-155, SER-603, SER-428 and SER-147, with encouraging early data for SER-155 in allo-HCT infections and immune checkpoint-related enterocolitis, though further trials depend on securing funding and collaborations.
Seres Therapeutics, Inc. reported a net loss of $19.9 million for the three months ended March 31, 2026, compared with net income of $32.7 million a year earlier, as revenue totaled only $0.4 million from a government grant.
Cash and cash equivalents were $29.8 million as of March 31, 2026, and management disclosed that these resources, together with forecasted cash flows, raise substantial doubt about the company’s ability to continue as a going concern without additional funding. Operating activities used $16.4 million of cash in the quarter.
The company continues to focus on live biotherapeutic product candidates SER-155, SER-603, SER-428 and SER-147 after the prior sale of its VOWST business. It implemented cost-reduction measures, including a workforce reduction of about 30%, incurring $0.9 million in restructuring charges, and modestly raised equity through an at-the-market program.
Seres Therapeutics (MCRB) reported Q3 2025 results. The company posted net income from continuing operations of $8.2 million for the quarter, driven by a $27.2 million gain on sale related to the VOWST business and $2.8 million of other income that included TSA reimbursements, against $22.8 million of operating expenses. Grant revenue was $351 thousand in Q3 2025, reflecting a CARB-X award tied to SER-155 development.
For the nine months ended September 30, 2025, net income from continuing operations was $21.0 million, including a year‑to‑date $79.6 million gain on the VOWST sale. Cash and cash equivalents were $47.6 million as of September 30, 2025, and total stockholders’ equity rose to $43.7 million from $13.8 million at year‑end 2024. The company disclosed substantial doubt about its ability to continue as a going concern based on current cash resources and forecasted operations.
Seres is advancing SER‑155, supported by a CARB‑X grant of up to $3.6 million, and recorded $1.0 million of restructuring costs tied to a ~25% workforce reduction announced on September 23, 2025. Shares outstanding were 8,764,664 as of September 30, 2025, and 9,046,519 as of October 31, 2025.